苏木精与顺铂、羟喜树碱等药物腹腔化疗对小鼠肝癌HepA细胞抑制作用的比较  

Comparison on hematoxylin, cisplatin, hydroxycamptothecine and ather medicine in celiac chemotherapy for mice hepatoma （HepA） model and their inhibitory effect

作　　者：任连生[1] 张蕻 白喜花[1] 闫磊[1] 杨永明[1] 赵娜[1] 

机构地区：[1]山西省肿瘤研究所动物实验室,太原030013 [2]山西省药晶检验所药理室

出　　处：《肿瘤研究与临床》2009年第2期84-86,共3页Cancer Research and Clinic

摘　　要：目的比较苏木精与丝裂霉素、顺铂、羟喜树碱等药物腹腔化疗对小鼠肝癌腹水型HepA细胞的抑制作用，探讨苏木精临床腹腔化疔的可行性。方法腹腔内接种HepA细胞，建立小鼠肝癌腹水瘤模型，接种后24h开始腹膜腔内注射给药，给药结束后动物常规饲养，定期测量小鼠体重，观察各组动物的生存状态，比较各组动物的平均生存时间。实验重复3次，比较3次实验的T／C值。结果对照组动物的平均生存时间为15．99～16．33d；苏木精组为36．35～39．81d；丝裂霉素组为35．77～40．06d；羟喜树碱组为20．79～38．47d；顺铂组为32．98～41．89d。综合比较以丝裂霉素组和苏木精组效果较好。结论苏木精腹腔化疗对小鼠移植性肝癌HepA细胞有显著的抑制作用，与丝裂霉素组比较差异无统计学意义，羟喜树碱与顺铂对HepA细胞的敏感性较差。Objective To compare the inhibitory effects to mice ascitic hepatoma （HepA） among hematoxylin, mitomycin, cisplatin, hydroxycamptothecine and other medicine in celiac chemotherapeutic route, probing into the credibility of hematoxylin in celiac chemotherapy. Methods Mice ascitic HepA model was set up by celiac inoculation of HepA strains. 24 h after the inoculation, intraperitoneal administration was done, then raising the mice as routine. Their body weights were measured regularly, living quality observed, mean survival times compared among these groups. Having repeated the above experiment three tines, T/C values obtained in the three experiments were compared one another. Results The awerage survival time of mice of control group （inoculated but no medicine used） was 15.99-16.33 d; that of hematoxylin group was 36.35-39.81 d; that of mitomycin group was 35.77-40.06 d; that of hydroxycamptothecine survived 20.79- 38.47 d; and that of cisplatin group was 32.98-41.89 d. A comprehensive comparison showed that mitomyein group and hematoxylin group had better effects. Conclusion Hematoxylin in celiac chemotherapy has an outstanding effect to the mice＇s transplanted HepA, no significant difference with mitomyein. However, hydroxycamptotheeine and cisplatin are not good enough.

关 键 词：苏木精 丝裂霉素 腹腔化疗 小鼠 HEPA 

分 类 号：R735[医药卫生—肿瘤]